Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Arch Neurol. 2010 Aug;67(8):949–956. doi: 10.1001/archneurol.2010.179

Figure 5.

Figure 5

Validation of the combined cerebrospinal fluid–derived β-amyloid protein 1–42 (CSF Aβ1–42)/CSF phosphorylated tau181P (CSF P-Tau181P) mixture model in 2 data sets. A, Patients with mild cognitive impairment who developed Alzheimer disease within 5 years after the CSF sample.2 B, Patients with autopsy-confirmed Alzheimer disease with mostly less than 1 year between CSF sample and autopsy (n = 68).12 Signature 1 is the Alzheimer disease signature (red); signature 2 is the healthy signature (green).